Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.53 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457430 | 0.88 | PDE4B (0.55) | PDE4BCAMK1DCSF1R | |
| SCHEMBL5405232 | 0.88 | PDE4B (0.54) | PDE4BCSF1RMTNR1B | |
| SCHEMBL4930190 | 0.87 | PDE4B (0.52) | PDE4BCAMK1DHSD17B10CSF1RMTNR1B | |
| SCHEMBL5404792 | 0.86 | PDE4B (0.51) | PDE4BCAMK1DCSF1RMTNR1B | |
| SCHEMBL5763422 | 0.83 | PDE4B (0.57) | PDE4BCSF1RMTNR1B | |
| SCHEMBL5413089 | 0.83 | PDE4B (0.49) | PDE4BCSF1R | |
| SCHEMBL8305598 | 0.81 | PDE4B (0.54) | PDE4BCSF1RMTNR1B | |
| SCHEMBL5763692 | 0.81 | PDE4B (0.54) | PDE4BCSF1R | |
| SCHEMBL31020770 | 0.81 | PDE4B (0.61) | PDE4BCSF1RMTNR1B | |
| SCHEMBL2505851 | 0.80 | PDE4B (0.59) | PDE4BCSF1RMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | claimed |
| JP-2007506717-A | — | — | 2007-03-22 | — | — | JP | claimed |
| EP-1673345-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | claimed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | claimed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-1673345-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030725-A1 | DERIVATIVES OF 3-AMINOCARBONYLQUINOLINE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION | GLAXO GROUP LIMITED (GB) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | PDE4B 1/4885CAMK1D 2595/4885HSD17B10 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.